Editors' Desk

  1. Top 5 Biosimilar Developments Of 2016

    In the spirit of this list-making season, I compiled what I thought were the five most important biosimilar-related triumphs in the past year. Many of these events were widely covered by the media and will play an influential role in how the biosimilar industry unfolds through 2017 and beyond.

  2. Are You The Future of Pharmaceutical Development?

    Pfizer's Bernie Huyghe and ADC Therapeutics' Michael Mulkerrin get bushwhacked with this question in a public forum. Their open replies will help each one of you to your own personal assessment. Be prepared for some soul searching.

  3. The Case For Moving The EMA To Ireland

    Relocating an organization as large as the EMA, which employs upwards of 1,000 people in London, will be no easy feat. As such, IDA Ireland, an agency that supports companies in Ireland and promotes foreign direct investments in the country, is working to compile information on why Ireland would be a good location for the EMA.

  4. Thomas Jefferson Hasn’t A Clue About Drug Development

    Understanding what went before, and the steadfast resolve to get to the future, are invaluable for reaching success in our industry. An illustrative and teaching example of this – including the past and future of outsourcing – is embodied in the people at a “thirty-year-old biotech.” They have little in common with Thomas Jefferson.

  5. Are CMOs Sufficiently Serving Biotechs?

    Louis Demers of Xoma knows what he wants in contract development and manufacturing organizations. For example, they should be networked with other service providers, and in mission-critical alignment. Can he get what he wants? Can any outsourcing leader at a biotech today? CMO consolidation may make it more difficult.

  6. Pharma Copycats In CMO Acquisition Strategy

    It used to be Pharma swept up emerging companies and their new technologies. Now CMOs do so as well. With Pharma, the technologies might end up on the shelf; not so with CMOs. But what about those emerging companies themselves? "If there are two guys thinking about doing a startup, they should do it,” we’re told.

  7. Pharma’s Potemkin Village On The River Of Outsourcing

    Grigory Potemkin was governor of war-ravaged New Russia in 1787. He’s said to have deployed a shiny “mobile village” along the Dnieper River to impress Catherine II (and the world) as she inspected the region from her barge. Were we, too, in the year 2016, deploying polished porticoes to hide a dimmer reality, at our Outsourced Pharma conferences?

  8. Pfizer Sets Example For CMOs In M&A Strategy

    “Big CMOs” acquire smaller contract development and manufacturing organizations in the same way as Big Pharma has historically acquired biotechs and smaller drug developers. This allegory resurfaced with Pfizer’s recent asset acquisition of Bind Therapeutics. What better modern-day model for CMOs to emulate? And we’ve just seen the cases of Catalent’s gobbling up Pharmatek, and Piramal lassoing Ash Stevens …

  9. Pfizer’s Key Questions For CMO Innovation

    As it turns out, Bernie Huyghe of Pfizer has a flair for interrogative statements. This has served him well as a leader in the biopharmaceuticals and vaccines outsourcing group at the company. It also helped lead a room full of bio/pharma and CMO professionals through the subject of innovation in the external development and supply chain.

  10. Pharma’s Super Heroes Of Innovation

    The supply chain is Pharma’s new super hero of innovation. But like any super hero, drug development and manufacturing providers struggle with a dual identity. One is conservative, steadfast, an order-taker. The other – the one Pharma wants today – breaks out into innovation and ingenious solutions. Can CMOs serve Metropolis in both capacities? We’ll find some answers in this sneak preview.